The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024, according to a new report by Grand View Research, Inc. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.
Rise
in number of oncological research projects to elucidate tumorigenesis and the
underlying mechanisms, consequently raising the demand for serial sampling,
diagnosis, and therapeutic manipulation, is a growth rendering driver of this
market.
Full Research Report On Next Generation Cancer Diagnostics Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market
Further Key
Findings from the Study Suggest:
- The qPCR & multiplexing
segment captured the largest market share in 2015 owing to the presence of
a wide product portfolio serving numerous applications in oncology R&D
- Next generation sequencing
services and solutions for oncology applications are anticipated to
be the fastest growing segment
- Oncology diagnostics in
biomarker discovery is expected witness growth as it subsequently
facilitates drug designing and identification of novel targets against
tumors
- On the basis of cancer type,
this vertical is segmented into lung, breast, colorectal, cervical, and
other forms of cancer
- Research projects to
establish the therapeutic index of anticancer cytotoxic drugs are one of
the key factors responsible for expected growth
- North America dominated the
market with respect to revenue generation in 2014 due to concerted efforts
directed toward the development of next generation sequencing technology
and companion diagnostics in personalized medicine
- Some of the key players
contributing significantly to the next generation cancer diagnostics
market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.;
Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke
Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.;
Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics,
Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market/request/rs1
Grand View Research has segmented
the next generation cancer diagnostics market on the basis of technology,
application, cancer type, function, and region:
Technology Outlook
(Revenue, USD Million, 2013 - 2024)
- Next Generation Sequencing
- qPCR & Multiplexing
- Lab-on- a- chip (LOAC) &
Reverse Transcriptase-PCR (RT-PCR)
- Protein Microarrays
- DNA Microarrays
Application Outlook
(Revenue, USD Million, 2013 - 2024)
- Biomarker Development
- CTC Analysis
- Proteomic Analysis
- Epigenetic Analysis
- Genetic Analysis
Cancer Type Outlook
(Revenue, USD Million, 2013 - 2024)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Others
Function Outlook
(Revenue, USD Million, 2013 - 2024)
- Therapeutic Monitoring
- Companion Diagnostics
- Prognostics
- Cancer Screening
- Risk Analysis
Regional Outlook
(Revenue, USD Million, 2013 - 2024)
- North America
- U.S
- Canada
- Europe
- Germany
- France
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Middle East & Africa
- South Africa
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment